Douglas K Kelsey

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial
    Douglas K Kelsey
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Pediatrics 114:e1-8. 2004
  2. ncbi Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study
    Rosalie J Bakken
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 24:449-60. 2008
  3. ncbi Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis
    Calvin R Sumner
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 16:699-711. 2006
  4. ncbi Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study
    David Michelson
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Ind, USA
    J Clin Psychiatry 68:582-7. 2007
  5. ncbi Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine
    Amy R Perwien
    Outcomes Research, US Medical Division, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Dev Behav Pediatr 25:264-71. 2004
  6. ncbi Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine
    Lenard A Adler
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    J Clin Psychopharmacol 26:648-52. 2006
  7. ncbi Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study
    Humberto Quintana
    Department of Psychiatry, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Clin Ther 29:1168-77. 2007
  8. ncbi Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome
    Thomas J Spencer
    Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Atten Disord 11:470-81. 2008

Detail Information

Publications8

  1. ncbi Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial
    Douglas K Kelsey
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Pediatrics 114:e1-8. 2004
    ..Another goal was to determine how early in treatment it was possible to discern a specific effect of the drug on ADHD symptoms...
  2. ncbi Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study
    Rosalie J Bakken
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 24:449-60. 2008
    ....
  3. ncbi Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis
    Calvin R Sumner
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 16:699-711. 2006
    ..This study tested the hypothesis that atomoxetine will provide significant therapeutic benefit for nocturnal enuresis in patients with the diagnosis of nocturnal enuresis...
  4. ncbi Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study
    David Michelson
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Ind, USA
    J Clin Psychiatry 68:582-7. 2007
    ..Addition of a noradrenergic intervention in patients poorly or partially responsive to SSRIs may improve outcomes, but few well-controlled studies testing this hypothesis have been reported...
  5. ncbi Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine
    Amy R Perwien
    Outcomes Research, US Medical Division, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Dev Behav Pediatr 25:264-71. 2004
    ..Findings demonstrate the positive impact of atomoxetine on HRQL in children with ADHD...
  6. ncbi Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine
    Lenard A Adler
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    J Clin Psychopharmacol 26:648-52. 2006
    ..Despite the existence of research demonstrating the effects of ADHD on certain aspects of life, the clinical trials of treatments for this disorder have focused primarily on efficacy and safety...
  7. ncbi Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study
    Humberto Quintana
    Department of Psychiatry, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Clin Ther 29:1168-77. 2007
    ..Recently developed nonpsychostimulant treatments have allowed certain patients to switch from a psychostimulant to a nonpsychostimulant. However, the outcomes of such switches have not been systematically studied...
  8. ncbi Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome
    Thomas J Spencer
    Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Atten Disord 11:470-81. 2008
    ..This study examines changes in severity of tics and ADHD during atomoxetine treatment in ADHD patients with Tourette syndrome (TS)...